WisdomTree BioRevolution FundCboe Consolidated Listings:WDNA
- LAST PRICE16.23
- TODAY'S CHANGE (%)0.38 (2.40%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close16.35 / 15.85
- Day Range
- 52 Week Range
- Volume501
- Overall Morningstar RatingNot Ratedout of 265 funds
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | WDNA |
|---|---|---|
| 09:39 ET | 200 | 16.3518 |
| 03:59 ET | 0 | 16.2309 |
Daily Premium/Discount
| Date | Daily Premium/Discount |
|---|---|
| 02/05/2024 | 0.03% |
| 02/06/2024 | -0.13% |
| 02/07/2024 | 0.00% |
| 02/08/2024 | -0.05% |
| 02/09/2024 | -0.12% |
| 02/12/2024 | -0.09% |
| 02/13/2024 | -0.30% |
| 02/15/2024 | -0.04% |
| 02/16/2024 | 0.00% |
| 02/20/2024 | -0.46% |
| 02/21/2024 Largest Discount | -0.47% |
| 02/22/2024 | -0.32% |
| 02/23/2024 | -0.38% |
| 02/26/2024 | -0.38% |
| 02/27/2024 | -0.38% |
| 02/28/2024 | -0.18% |
| 02/29/2024 | -0.27% |
| 03/01/2024 | -0.34% |
| 03/04/2024 | -0.39% |
| 03/05/2024 | -0.29% |
| 03/06/2024 | -0.42% |
| 03/08/2024 | -0.30% |
| 03/11/2024 | -0.41% |
| 03/12/2024 | -0.28% |
| 03/13/2024 | -0.41% |
| 03/14/2024 Largest Premium | 0.40% |
| 03/15/2024 | 0.13% |
| 03/18/2024 | 0.25% |
| 03/19/2024 | 0.28% |
| 03/20/2024 | 0.31% |
| 03/21/2024 | 0.05% |
| 03/22/2024 | 0.38% |
| 03/25/2024 | 0.16% |
| 03/26/2024 | 0.01% |
| 03/27/2024 | 0.00% |
| 03/28/2024 | 0.14% |
| 04/01/2024 | 0.15% |
| 04/02/2024 | 0.14% |
| 04/03/2024 | 0.13% |
| 04/04/2024 | 0.07% |
| 04/05/2024 | 0.12% |
| 04/09/2024 | 0.00% |
| 04/10/2024 | 0.11% |
| 04/11/2024 | 0.04% |
| 04/12/2024 | -0.11% |
| 04/15/2024 | -0.07% |
| 04/16/2024 | 0.05% |
| 04/17/2024 | 0.03% |
| 04/18/2024 | -0.02% |
| 04/19/2024 | -0.24% |
| 04/22/2024 | -0.09% |
| 04/23/2024 | -0.03% |
| 04/24/2024 | -0.15% |
| 04/25/2024 | -0.14% |
| 04/26/2024 | -0.08% |
| 04/29/2024 | -0.23% |
| 04/30/2024 | -0.21% |
| 05/01/2024 | -0.13% |
| 05/02/2024 | -0.23% |
| 05/03/2024 | -0.20% |
| US Stock | 83.1% |
|---|---|
| Non-US Stock | 16.9% |
| Cash | 0 |
| Convertible | 0 |
| Non-US Bond | 0 |
| Other | 0 |
| Healthcare | 82.4% |
|---|---|
| Basic Mat. | 12.3% |
| Consumer Defensive | 4.1% |
| Consumer Cyclical | 0.6% |
| Communication Services | 0 |
| Energy | 0 |
| Financial Serv.s | 0 |
| Industrials | 0 |
| Real Estate | 0 |
| Technology | 0 |
| Utilities | 0 |
| United States | 83.1% |
|---|---|
| Europe | 4.9% |
| Asia/Oceania | 2.1% |
| Canada | 0.9% |
| Africa | 0 |
| Latin America | 0 |
| Company Name sortable | Position sortable | Allocation sortable | Allocation sortable1 Month Change | Market Value sortable |
|---|---|---|---|---|
Novonesis AS Class B | Long | 2.7% | 0.00% | $61.5K |
Twist Bioscience Corp | Long | 2.6% | 0.00% | $58.8K |
Iovance Biotherapeutics Inc | Long | 2.4% | 0.00% | $55.0K |
Blueprint Medicines Corp | Long | 2.4% | 0.00% | $54.8K |
Geron Corp | Long | 2.3% | 0.00% | $54.1K |
Eli Lilly and Co | Long | 2.2% | 0.00% | $51.6K |
Natera Inc | Long | 2.2% | 0.00% | $50.5K |
Vericel Corp | Long | 2.1% | 0.00% | $47.8K |
Agios Pharmaceuticals Inc | Long | 1.8% | 0.00% | $40.9K |
Fate Therapeutics Inc | Long | 1.8% | 0.00% | $40.7K |
Reports
Morningstar Ratings
| Time Horizon | Star Rating |
|---|---|
| Overall Rating | Not Rated |
| 3 Year Rating | Not Rated |
| 5 Year Rating | Not Rated |
| 10 Year Rating | Not Rated |
Past performance is no guarantee of future results. The ratings reflect historical risk-adjusted performance, and the overall rating is derived from a weight average of the fund's 3, 5, and 10 year (Morningstar Rating) metrics.
Style Box is calculated only using the long position holdings of the portfolio.
Best Fit Index | WisdomTree BioRevolution USD |
|---|---|
Category | |
Sponsor | WisdomTree Asset Management Inc |
Inception | June 1, 2021 |
The investment seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution Index (“indexâ€). The fund generally uses a representative sampling strategy to achieve its investment objective, meaning it generally will invest in a sample of the securities in the index whose risk, return and other characteristics resemble the risk, return and other characteristics of the index as a whole. The index is designed to provide exposure to equity securities of exchange listed companies globally that will be significantly transformed by advancements in genetics and biotechnology. The fund is non-diversified.
| Total Net Assets | $2.3M |
|---|---|
| Shares Out. | 150.0K |
| Net Asset Value (NAV) | $15.89 |
| Prem/Discount to NAV | -0.23% |
| P/E Ratio | --- |
| Dividend Yield | 0.83% |
| Dividend per Share | 0.14 USD |
| Ex-Dividend Date | 12/22/2023 |
| Dividend Payment Date | 12/28/2023 |
| Beta | --- |
| Morningstar Investment Style | Health |
| Equity Style | Mid Cap Blend |
| Credit Quality / Duration | --- |
| Actual Management Fee | 0.45% |
|---|---|
| Actual Mgmt. Expense Ratio (MER) | 0.45% |